Ionis Pharmaceuticals Inc (IONS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$58.09-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IONS
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(25.0) + peer(0.2*0.0) + term(0.0) → 8.75% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On July 29, 2026, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2026. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equi…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On April 29, 2026, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to eq…
Results of Operations and Financial Condition. On February 25, 2026, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation…
Results of Operations and Financial Condition. On January 12, 2026, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing TRYNGOLZA ® 2025 preliminary U.S. net product sales of $105 million. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The preliminary selected financial results reported by the Company are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of compl…
Results of Operations and Financial Condition. On October 29, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related…
Results of Operations and Financial Condition. On July 30, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equi…
Results of Operations and Financial Condition. On April 30, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to eq…
Results of Operations and Financial Condition. On February 19, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation…
Results of Operations and Financial Condition. On November 6, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related…
Results of Operations and Financial Condition. On August 1, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equ…
Results of Operations and Financial Condition. On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related to equit…
Results of Operations and Financial Condition. On February 21, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2023. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation…
Results of Operations and Financial Condition. On November 2, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023. In addition to disclosing results that are determined in accordance with Generally Accepted Accounting Principles (“ GAAP ”), the Company also discloses pro forma or non-GAAP results of operations, which are adjusted from GAAP to exclude non-cash compensation expense related…